| __timestamp | BioMarin Pharmaceutical Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 570979 |
| Thursday, January 1, 2015 | 152008000 | 2185000 |
| Friday, January 1, 2016 | 209620000 | 4554000 |
| Sunday, January 1, 2017 | 241786000 | 3605000 |
| Monday, January 1, 2018 | 315264000 | 5527000 |
| Tuesday, January 1, 2019 | 359466000 | 5234000 |
| Wednesday, January 1, 2020 | 524272000 | 6126000 |
| Friday, January 1, 2021 | 470515000 | 6784000 |
| Saturday, January 1, 2022 | 483669000 | 7592000 |
| Sunday, January 1, 2023 | 577065000 | 11450000 |
| Monday, January 1, 2024 | 580235000 |
Unleashing the power of data
In the competitive world of biotechnology, cost efficiency is a critical factor for success. This analysis compares the cost of revenue efficiency between BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc. over the past decade. From 2014 to 2023, BioMarin has consistently demonstrated a robust cost management strategy, with its cost of revenue increasing by approximately 345%, from $130 million to $577 million. In contrast, Travere Therapeutics, Inc. has shown a more modest growth of around 1,900%, starting from a mere $570,979 to $11.45 million.
While BioMarin's larger scale reflects its established market presence, Travere's rapid growth highlights its aggressive expansion strategy. This comparison underscores the diverse approaches within the biotech sector, where both scale and growth rate play pivotal roles in shaping a company's financial health.
Analyzing Cost of Revenue: Novo Nordisk A/S and Travere Therapeutics, Inc.
Analyzing Cost of Revenue: Sanofi and BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
BioMarin Pharmaceutical Inc. vs ACADIA Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.
ACADIA Pharmaceuticals Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.